A minimal PBPK model to accelerate preclinical development of drugs against tuberculosis

A minimal PBPK model to accelerate preclinical development of drugs against tuberculosis

Introduction: Understanding drug exposure at disease target sites is pivotal to profiling new drug candidates in terms of tolerability and efficacy. Such quantification is particularly tedious for anti-tuberculosis (TB) compounds as the heterogeneous pulmonary microenvironment due to the infection m...

Full description

Bibliographic Details
Main Authors: Federico Reali, Anna Fochesato, Chanchala Kaddi, Roberto Visintainer, Shayne Watson, Micha Levi, Véronique Dartois, Karim Azer, Luca Marchetti
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-01-01
Series:Frontiers in Pharmacology
Subjects:
minimal PBPK model
mPBPK
antituberculosis agents
modeling
simulation
tuberculosis
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2023.1272091/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2023.1272091/full

Similar Items